CANF Can-Fite BioPharma Ltd.

13,427

$2.44

$0.09

(3.83%)

Today

Watchers	13,427
52-Wk Low	$1.52
52-Wk High	$8.40

Market Cap	$38.08M
Volume (M)	4,302.00
52-Wk High	$8.40
52-Wk Low	$1.52

Fundamentals

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with NamodenosonBusiness Wire • almost 2 years ago

--- - 'Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has enrolled the first patient in a Phase IIb study of its drug candidate Namodenoson...'

Share to Feed

Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 MillionGlobe Newswire • almost 2 years ago

--- - 'PETACH TIKVA, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the agreement by an healthcare-...'

Cancer Immunotherapy Gets Boost from Newly Engineered NanoparticlesPR Newswire • over 3 years ago

--- - Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles FN Media Group Presents USA News Group News Commentary PR Newswire LOS ANGELES, June 25, 2020 LOS ANGELES, June 25, 2020 /PRNewswire/ --USA News Group In a major ...

Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver CancerBusiness Wire • over 3 years ago

--- - 'Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has successfully concluded a meeting with the Scientific Advice Working Party (SAWP) of...'

Can-Fite BioPharma Announces Pricing of $5 Million Public OfferingGlobe Newswire • almost 4 years ago

--- - 'PETACH TIKVA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the pricing of a public offering ...'

New Data From Hadassah Medical Center Lab Show Can-Fites Namodenoson Induces Weight LossBusiness Wire • almost 4 years ago

--- - 'Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadis lab ...'

Findings from Can-Fites Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking SessionBusiness Wire • over 4 years ago

--- - 'Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that data from its recently completed Phase II trial in patients with hepatocellular cancer (HCC), ...'

Can-Fite BioPharma Announces $6 Million Registered Direct OfferingGlobe Newswire • over 4 years ago

--- - 'PETACH TIKVA, Israel, May 20, 2019 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a ...'